Series Overview:

The Perelman School of Medicine at the University of Pennsylvania and ViralEd are proud to announce the extension of this ground-breaking CME activity. Mirroring academic grand rounds programs, these CME-certified sessions combine traditional academic grand rounds with the innovation and convenience of telemedicine. The "HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania" is delivered live via the Internet every Thursday at 12:00pm Eastern Time and is available for on-demand viewing immediately following the live broadcast.

Presentations cover the most important and current topics in HIV/AIDS and are delivered by the top experts in the field. They are designed to be immediately relevant to practicing HIV clinicians and many are case-based. The final 10 minutes of each one-hour educational activity consists of a live question and answer period, with the presenting faculty member available to answer questions asked by attendees using the webinar interface. These weekly grand rounds are intended to provide clinicians with convenient and easily accessible knowledge and clinical skills they need to provide the best medical care for their HIV-positive patients.

Each session may be broadcast via your Internet connection in your conference room or auditorium for large groups to view, or individually to your personal computer at your convenience. Simply register at www.viraled.com/grandrounds for easy access.

Target Audience:

The program has been designed for physicians, fellows, residents, medical students, nurses, nurse practitioners, physician assistants and allied health professionals in the medical specialties of Dermatology, Nephrology, Hematology/Oncology and Psychiatry as well as OB/GYN physicians, Osteo-specialists, Infectious Disease specialists, Public Health professionals and other clinicians interested and involved in the care of patients with HIV/AIDS.

Commercial Support Acknowledgement:

HIV Grand Rounds is supported by educational grants from Gilead Sciences Medical Affairs and Janssen Therapeutics, Division of Janssen Products, LP

Learning Objectives for the Series:

Upon completion of the educational activity, participants should be able to:

• Improve knowledge and ability to use ARV therapy successfully;
• Improve the knowledge of how drug adverse events, drug pharmacokinetics and patient adherence can affect ARV success and through the application of this knowledge avoid morbidity and mortality;
• Improve knowledge of opportunistic infections and co-morbidities that may affect HIV-positive patients and increase their risk for morbidity and Mortality;
• Improve understanding of the importance of individualizing the care of each HIV-positive patient.

Course Directors:

	Calvin J. Cohen, MD, MS Research Director CRI New England Clinical Instructor Harvard Medical School Boston, Massachusetts		Ian Frank, MD Professor of Medicine, Director, Clinical Therapeutics Program Penn Center for AIDS Research Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania
	John G. Bartlett, MD Chief, Division of Infectious Diseases Stanhope Bayne Jones Professor of Medicine Director, HIV Care Program Johns Hopkins School of Medicine Baltimore, Maryland

Faculty:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and ViralEd, Inc.. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.

Discussion of Investigational and/or Off-label Use of commercial products and devices:

The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

Faculty members will disclose to participants any discussions of off-label and/or investigational uses of pharmaceutical products within their presentations.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

register: